+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

  • ID: 4851384
  • Report
  • March 2018
  • Region: Global
  • 177 pages
  • Transparency Market Research
1 of 2

Global MRSA Drugs Market: Overview

This report on the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market analyzes the current and future scenario of the global market. Rise in private and public funding for R&D of novel anti-MRSA drug molecules, increase in prevalence of MRSA infections, and their improved screening are boosting the growth of the global MRSA drugs market. According to CDC, two in every 100 people carry MRSA. Introduction of generic drugs for the MRSA treatment, and upsurge in the consumption of antibiotics in the developing countries are some of the factors expected to drive the growth of global MRSA drugs market during the forecast period.

The MRSA drugs market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on drug class, route of administration, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the report comprises epidemiological assessment of MRSA infection, in terms of causes, complications, current & future treatment options for MRSA, along with its prevalence rate in key countries. The report contains comparative analysis of key companies operating in the global MRSA drugs market, in terms of strategic developments, current and future market positioning, and their key differential parameters, to help understand the competitive landscape in the market. Moreover, the global corporate scenario is provided in the report with major pipeline products of emerging and established pharmaceutical manufacturers, and their respective dosage forms. This report also provides market attractiveness and its analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global MRSA drugs market.

Global MRSA Drugs Market: Key Segments

Based on the drug class, the global MRSA drugs market is segmented into lipopeptide, oxazolidinone, cephalosporin, tetracycline, lipoglycopeptide, folate antagonist, and others. Lipopeptide accounted for highest market share in 2016, owing to the diversified distribution of daptomycin (lipopeptide) across the globe by key distributors in 2016. Others drug class is projected to expand at relatively significant CAGR during 2017-2025, which is attributable to the rising incidence of community-acquired MRSA infection. Different types of route of administration in the MRSA drugs market are oral and parenteral. Parenteral segment dominated the market in terms of market share in 2016, and is expected to continue to lead the global market during forecast period. However, oral segment is likely to expand during 2017-2025, due to presence of numerous oral vaccines against MRSA infection in the developmental phase by key companies. Various distribution channels in the global MRSA market are hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacy held maximum market share in 2016, and is expected to remain dominant by 2025 in terms of revenue. However, online pharmacy is likely to expand with maximum CAGR owing to the rising adoption of the population for digital platform. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global MRSA Drugs Market: Regional Outlook

Geographically, the global MRSA drugs has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, Russia, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global MRSA drugs based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market

4. Market Overview
4.1. Drug Class Overview
4.2. Global MRSA Drugs Market Outlook

5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities

6. Epidemiological Assessment of Methicillin-resistant Staphylococcus Aureus (MRSA)

7. MRSA Drugs: Pipeline Analysis

8. MRSA Drugs Market: Competitive Landscape of Key Players

9. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Drug Class
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast By Drug Class, 2015-2025
9.3.1. Lipopeptide
9.3.2. Oxazolidinone
9.3.3. Cephalosporin
9.3.4. Tetracycline
9.3.5. Lipoglycopeptide
9.3.6. Folate Antagonist
9.3.7. Others
9.4. Market Attractiveness By Drug Class
9.5 Key Trends

10. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Route of Administration
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast By Route of Administration, 2015-2025
10.3.1. Oral
10.3.2. Parenteral
10.4. Market Attractiveness By Route of Administration
10.5. Key Trends

11. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings/Developments
11.3. Market Value Forecast By Distribution Channel, 2015-2025
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Market Attractiveness By Distribution Channel
11.5 Key Trends

12. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Region
12.1. Key Findings
12.2. Market Value Forecast By Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness By Country/Region

13. North America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2015-2025
13.2.1. Lipopeptide
13.2.2. Oxazolidinone
13.2.3. Cephalosporin
13.2.4. Tetracycline
13.2.5. Lipoglycopeptide
13.2.9. Folate Antagonist
13.2.7. Others
13.3. Market Value Forecast By Route of Administration, 2015-2025
13.3.1. Oral
13.3.2. Parenteral
13.4. Market Value Forecast By Distribution Channel, 2015-2025
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Market Value Forecast By Country, 2015-2025
13.5.1. U.S.
13.5.2. Canada
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country

14. Europe Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2.Market Value Forecast By Drug Class, 2015-2025
14.2.1. Lipopeptide
14.2.2. Oxazolidinone
14.2.3. Cephalosporin
14.2.4. Tetracycline
14.2.5. Lipoglycopeptide
14.2.6. Folate Antagonist
14.2.7. Others
14.3.Market Value Forecast By Route of Administration, 2015-2025
14.3.1. Oral
14.3.2. Parenteral
14.4.Market Value Forecast By Distribution Channel, 2015-2025
14.4.1. Hospital Pharmacy
14.4.2. Retail Pharmacy
14.4.3. Online Pharmacy
14.5.Market Value Forecast By Country, 2015-2025
14.5.1. Germany
14.5.2. U.K.
14.5.3. France
14.5.4. Spain
14.5.5. Italy
14.5.6. Russia
14.5.7. Rest of Europe
14.6.Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country

15. Asia Pacific Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
15.1.Introduction
15.1.1. Key Findings
15.2.Market Value Forecast By Drug Class, 2015-2025
15.2.1. Lipopeptide
15.2.2. Oxazolidinone
15.2.3. Cephalosporin
15.2.4. Tetracycline
15.2.5. Lipoglycopeptide
15.2.6. Folate Antagonist
15.2.7. Others
15.3.Market Value Forecast By Route of Administration, 2015-2025
15.3.1. Oral
15.3.2. Parenteral
15.4.Market Value Forecast By Distribution Channel, 2015-2025
15.4.1. Hospital Pharmacy
15.4.2. Retail Pharmacy
15.4.3. Online Pharmacy
15.5.Market Value Forecast By Country, 2015-2025
15.5.1. China
15.5.2. Japan
15.5.3. India
15.5.4. Australia & New Zealand
15.5.5. Rest of Asia Pacific
15.6.Market Attractiveness Analysis
15.6.1. By Drug Class
15.6.2. By Route of Administration
15.6.3. By Distribution Channel
15.6.4. By Country

16. Latin America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
16.1.Introduction
16.1.1. Key Findings
16.2.Market Value Forecast By Drug Class, 2015-2025
16.2.1. Lipopeptide
16.2.2. Oxazolidinone
16.2.3. Cephalosporin
16.2.4. Tetracycline
16.2.5. Lipoglycopeptide
16.2.6. Folate Antagonist
16.2.7. Others
16.3.Market Value Forecast By Route of Administration, 2015-2025
16.3.1. Oral
16.3.2. Parenteral
16.4.Market Value Forecast By Distribution Channel, 2015-2025
16.4.1. Hospital Pharmacy
16.4.2. Retail Pharmacy
16.4.3. Online Pharmacy
16.5.Market Value Forecast By Country, 2015-2025
16.5.1. Brazil
16.5.2. Mexico
16.5.3. Rest of Latin America
16.6.Market Attractiveness Analysis
16.6.1. By Drug Class
16.6.2. By Route of Administration
16.6.3. By Distribution Channel
16.6.4. By Country

17. Middle East & Africa Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
17.1.Introduction
17.1.1. Key Findings
17.2.Market Value Forecast By Drug Class, 2015-2025
17.2.1. Lipopeptide
17.2.2. Oxazolidinone
17.2.3. Cephalosporin
17.2.4. Tetracycline
17.2.5. Lipoglycopeptide
17.2.6. Folate Antagonist
17.2.7. Others
17.3.Market Value Forecast By Route of Administration, 2015-2025
17.3.1. Oral
17.3.2. Parenteral
17.4.Market Value Forecast By Distribution Channel, 2015-2025
17.4.1. Hospital Pharmacy
17.4.2. Retail Pharmacy
17.4.3. Online Pharmacy
17.5.Market Value Forecast By Country, 2015-2025
17.5.1. GCC Countries
17.5.2. South Africa
17.5.3. Israel
17.5.4. Rest of Middle East & Africa
17.6.Market Attractiveness Analysis
17.6.1. By Drug Class
17.6.2. By Route of Administration
17.6.3. By Distribution Channel
17.6.4. By Country

18. Competition Landscape
18.1.Market Player - Competition Matrix (By Tier and Size of companies)
18.2.Market Share Analysis By Company (2016)
18.3. Company Profiles
18.5.1. Basilea Pharmaceutica Ltd.
18.3.1.1. Overview
18.3.1.2.Financials
18.3.1.3.Recent Developments
18.3.1.4.SWOT Analysis
18.3.1.5.Strategic Overview
18.3.2. The Medicines Company
18.3.2.1. Overview
18.3.2.2.Financials
18.3.2.3.Recent Developments
18.3.2.4.SWOT Analysis
18.3.2.5.Strategic Overview
18.3.3. Theravance Biopharma
18.3.3.1. Overview
18.3.3.2.Financials
18.3.3.3.Recent Developments
18.3.3.4.SWOT Analysis
18.3.3.5.Strategic Overview
18.3.4. Allergan
18.3.4.1. Overview
18.3.4.2.Financials
18.3.4.3.Recent Developments
18.3.4.4.SWOT Analysis
18.3.4.5.Strategic Overview
18.3.5. Merck & Co., Inc.
18.3.5.1. Overview
18.3.5.2.Financials
18.3.5.3.Recent Developments
18.3.5.4.SWOT Analysis
18.3.5.5.Strategic Overview
18.3.6. Pfizer, Inc.
18.3.6.1. Overview
18.3.6.2.Financials
18.3.6.3.Recent Developments
18.3.6.4.SWOT Analysis
18.3.6.5.Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll